Physician profile
Lei Chen
NPI 1376875641
$4,520.82
in general payments reported to CMS, 2019-2025
25 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $351 · 2021: $325 · 2022: $1,067 · 2023: $943 · 2024: $782 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.78 |
| Education | $203.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $667.89 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $534.23 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $488.74 | 2020-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $467.94 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $267.37 | 2019-2024 | Veltassa |
| Ardelyx, INC. | $263.18 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $242.35 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $218.79 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $215.17 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $197.57 | 2022-2025 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $169.70 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $134.55 | 2022-2025 | Tarpeyo |
| Amgen INC. | $96.98 | 2019-2024 | Tavneos |
| Mallinckrodt Enterprises LLC | $83.95 | 2019 | |
| Ani Pharmaceuticals, INC. | $70.55 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $59.99 | 2019-2023 | Renal - Extraneal Solution |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.26 | 2022 | |
| Horizon Therapeutics Plc | $54.37 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $50.48 | 2023-2024 | |
| Scpharmaceuticals INC. | $46.62 | 2025 | |
| Aurinia Pharma U.S., INC. | $43.50 | 2021-2023 | Lupkynis |
| Lilly USA, LLC | $24.96 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.11 | 2024 | |
| Novo Nordisk INC | $22.90 | 2023 | Rybelsus, Ozempic |
| Kyowa Kirin, INC. | $17.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lei Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.